 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || tigulixostat (LC350189) / LG Chem
Enrollment closed: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects (clinicaltrials.gov) - Sep 19, 2024
P2, N=84, Active, not recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting --> Active, not recruiting
- |||| tigulixostat (LC350189) / LG Chem
New P2 trial: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects (clinicaltrials.gov) - Jul 15, 2024
P2, N=80, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- tigulixostat (LC350189) / LG Chem
PRECLINICAL IN VITRO AND IN VIVO EFFICACY STUDIES OF TIGULIXOSTAT, A SELECTIVE NON-PURINE XANTHINE OXIDASE INHIBITOR () - May 29, 2024 - Abstract #EULAR2024EULAR_2982;
In preclinical evaluation of efficacy, TGX inhibited XO enzyme activity and lowered uric acid at a level comparable to febuxostat. In addition, TGX, with no structural resemblance to purine base, does not affect the pyrimidine metabolism and its related kidney toxicity in mice.
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) - Mar 22, 2024
P1, N=30, Completed, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
In addition, TGX, with no structural resemblance to purine base, does not affect the pyrimidine metabolism and its related kidney toxicity in mice. Not yet recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024
- || tigulixostat (LC350189) / LG Chem
New P1 trial: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor) (clinicaltrials.gov) - Feb 25, 2024
P1, N=30, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
- || tigulixostat (LC350189) / LG Chem
Clinical, Journal: Comment on serum urate-lowering efficacy and safety of Tigulixostat in gout patients with hyperuricemia: A randomized, double-blind, placebo-controlled, dose-finding trial. (Pubmed Central) - Feb 3, 2024
Not yet recruiting --> Completed | Trial completion date: Jun 2024 --> Mar 2024 No abstract available
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Effect of Tigulixostat on the Pharmacokinetics of Theophylline (clinicaltrials.gov) - Jan 2, 2024
P1, N=24, Completed, Sponsor: LG Chem
- || Review, Journal: Pipeline Therapies for Gout. (Pubmed Central) - Dec 22, 2023
A new xanthine oxidase inhibitor (XOI), tigulixostat, is under study...Dapansutrile, an oral agent under investigation, inhibits activation of the NLRP3 inflammasome and may be an effective anti-inflammatory. New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects.
- |||||| tigulixostat (LC350189) / LG Chem
Enrollment open: EURELIA2: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (clinicaltrials.gov) - May 23, 2023
P3, N=2542, Recruiting, Sponsor: LG Chem
New treatments for gout that are under study may work in the setting of comorbidities, simplify management, utilize new mechanisms, or have reduced side effects. Not yet recruiting --> Recruiting
- |||| tigulixostat (LC350189) / LG Chem
Clinical: 📑ECA fase 2 muestra eficacia significativa de tigulixostat frente a placebo en reducción de uricemia en #gota 🎯Úrico <5 mg/dl a 12 semanas: -Placebo: 2.9% -TGX 50: 47.1% -TGX 100: 44.7% -TGX 200g: 62.2% #gout #uricacid #tigulixostat @geacser @KenSaag https://t.co/1uXyWbJzbk (Twitter) - Jan 22, 2023
- || tigulixostat (LC350189) / LG Chem
Clinical, Journal: Serum urate-lowering efficacy and safety of tigulixostat in gout patients with hyperuricemia: a randomized, double-blind, placebo-controlled, dose-finding trial (CLUE). (Pubmed Central) - Jan 18, 2023
Not yet recruiting --> Recruiting Tigulixostat significantly lowered sUA levels compared to placebo at all doses used with an acceptable safety profile.
- |||||| tigulixostat (LC350189) / LG Chem
Enrollment open: EURELIA1: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (clinicaltrials.gov) - Jan 10, 2023
P3, N=350, Recruiting, Sponsor: LG Chem
Tigulixostat significantly lowered sUA levels compared to placebo at all doses used with an acceptable safety profile. Not yet recruiting --> Recruiting
- |||||||||| tigulixostat (LC350189) / LG Chem
New P3 trial: EURELIA1: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (clinicaltrials.gov) - Oct 19, 2022
P3, N=350, Not yet recruiting, Sponsor: LG Chem
- |||||||||| tigulixostat (LC350189) / LG Chem
New P3 trial: EURELIA2: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients (clinicaltrials.gov) - Oct 19, 2022
P3, N=2542, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
Trial completion: Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects (clinicaltrials.gov) - Jan 6, 2022
P1, N=37, Completed, Sponsor: LG Chem
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- || tigulixostat (LC350189) / LG Chem
Trial completion: Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults (clinicaltrials.gov) - Jan 6, 2022
P1, N=23, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed Not yet recruiting --> Completed
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects (clinicaltrials.gov) - Jul 18, 2021
P1, N=36, Not yet recruiting, Sponsor: LG Chem
- ||| tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Jun 18, 2021
P2, N=156, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> May 2021
- || tigulixostat (LC350189) / LG Chem
New P1 trial: Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults (clinicaltrials.gov) - May 12, 2021
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
Enrollment closed: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Apr 27, 2021
P2, N=152, Active, not recruiting, Sponsor: LG Chem
Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> May 2021 Recruiting --> Active, not recruiting
- || tigulixostat (LC350189) / LG Chem
Trial completion date, Trial primary completion date: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Sep 21, 2020
P2, N=152, Recruiting, Sponsor: LG Chem
Recruiting --> Active, not recruiting Trial completion date: May 2021 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Apr 2021
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial primary completion date: Renal PK Study of LC350189 (clinicaltrials.gov) - Sep 19, 2020
P1, N=37, Completed, Sponsor: LG Chem
Trial completion date: May 2021 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Apr 2021 Recruiting --> Completed | Trial primary completion date: May 2020 --> Sep 2020
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults (clinicaltrials.gov) - Jun 25, 2020
P1, N=24, Completed, Sponsor: LG Chem
Recruiting --> Completed | Trial primary completion date: May 2020 --> Sep 2020 Not yet recruiting --> Completed | Trial completion date: May 2020 --> Feb 2020
- || tigulixostat (LC350189) / LG Chem
Trial completion: Mass Balance Study of [14C]LC350189 in Healthy Volunteers (clinicaltrials.gov) - Jun 25, 2020
P1, N=6, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed | Trial completion date: May 2020 --> Feb 2020 Not yet recruiting --> Completed
- || tigulixostat (LC350189) / LG Chem
Trial completion, Trial completion date: The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. (clinicaltrials.gov) - Jun 25, 2020
P1, N=24, Completed, Sponsor: LG Chem
Not yet recruiting --> Completed Not yet recruiting --> Completed | Trial completion date: Feb 2020 --> Nov 2019
- | tigulixostat (LC350189) / LG Chem
Trial completion date: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Jan 22, 2020
P2, N=190, Recruiting, Sponsor: LG Chem
Not yet recruiting --> Completed | Trial completion date: Feb 2020 --> Nov 2019 Trial completion date: Oct 2020 --> May 2021
- ||| tigulixostat (LC350189) / LG Chem
Enrollment open: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Jan 13, 2020
P2, N=190, Recruiting, Sponsor: LG Chem
Trial completion date: Oct 2020 --> May 2021 Not yet recruiting --> Recruiting
- || tigulixostat (LC350189) / LG Chem
Enrollment open: Renal PK Study of LC350189 (clinicaltrials.gov) - Nov 27, 2019
P1, N=48, Recruiting, Sponsor: LG Chem
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || tigulixostat (LC350189) / LG Chem
New P1 trial: The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults (clinicaltrials.gov) - Nov 4, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- | tigulixostat (LC350189) / LG Chem
New P1 trial: Mass Balance Study of [14C]LC350189 in Healthy Volunteers (clinicaltrials.gov) - Aug 28, 2019
P1, N=6, Not yet recruiting, Sponsor: LG Chem
- | tigulixostat (LC350189) / LG Chem
New P1 trial: Renal PK Study of LC350189 (clinicaltrials.gov) - Aug 26, 2019
P1, N=48, Not yet recruiting, Sponsor: LG Chem
- ||||| tigulixostat (LC350189) / LG Chem
New P2 trial: A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia (clinicaltrials.gov) - Apr 30, 2019
P2, N=228, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
New P1 trial: The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults. (clinicaltrials.gov) - Apr 24, 2019
P1, N=24, Not yet recruiting, Sponsor: LG Chem
- || tigulixostat (LC350189) / LG Chem
Enrollment change: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (clinicaltrials.gov) - Jun 9, 2013
P1, N=129, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting N=102 --> 129
- ||| tigulixostat (LC350189) / LG Chem
Trial completion: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (clinicaltrials.gov) - Jun 9, 2013
P1, N=129, Completed, Sponsor: LG Life Sciences
N=102 --> 129 Recruiting --> Completed